Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

It is the purpose of this study to determine the concentration of 3 allergens (goldnatriumthiosulphate, methyldibromoglutharonitrile [MDBGN], parthenolide) for diagnosing allergic contact dermatitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mekos Laboratories AS
• Treatments: Parthenolide

Criteria

Inclusion Criteria:

• Positive MDBGN patch test within the latest 5 years or positive Parthenolide patch test within the latest 5 years or positive Goldnatriumthiosulphate patch test within the latest 5 years.

• Age more or equal to 18 years.

• Signed informed consent.

Exclusion Criteria:

• Topical treatment with corticosteroids or immunosuppressives during the latest 7 days on the test area or near the test area.

• Systemic treatment with corticosteroids or immunosuppressives during the latest 7 days.

• Treatment with UV-light during the latest 3 weeks.

• Widespread active dermatitis or dermatitis on test area.

• Breast-feeding, pregnancy or insufficient contraception. If any doubt a negative urine-pregnancy test should be demonstrated or the patch test should be postponed one period.

• Subjects not able to cooperate.

• Participation in other clinical studies during the study period and 3 weeks prior to study start.